79 results about "Nephritis" patented technology

Disclosed herein is a method for treating immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) with the factor B inhibitor iptacopan or a pharmaceutically acceptable salt thereof (e.g., iptacopan hydrochloride).

The invention provides an antrodia camphorata sporocarp extract, which is prepared from the following raw materials in parts by weight: 20 to 24 parts of wild ganoderma lucidum extract, 8 to 12 parts of herba taraxaci and 8 to 12 parts of bolete. The antrodia camphorata sporocarp extract disclosed by the invention contains various physiologically active components such as triterpenoids, polysaccharides, superoxide disproportionated enzymes, adenosine, proteins (containing immune proteins), vitamins, trace elements, nucleic acid, lectin, amino acid, sterols, lignin, blood pressure stabilizing substances and the like; the traditional Chinese medicine composition can relieve various tumors such as hangover, gastrointestinal discomfort, heatstroke, hypertension, virus infection, diabetes mellitus, nephritis, liver cirrhosis and liver cancer, has the effects of resisting oxidation, resisting inflammation, inhibiting hypertension, protecting liver nerves, inhibiting tumor growth and the like, can bidirectionally regulate immunity and protect the liver, can also treat tumors at multiple targets, and has a wide application prospect. The discomfort of a patient in an anti-tumor process is reduced.

The mechanisms driving the development of extracapillary lesions in focal segmental glomerulosclerosis (FSGS) and crescentic glomerulonephritis (CGN) remain poorly understood. A key question is how parietal epithelial cells (PECs) invade glomerular capillaries, thereby promoting injury and kidney failure. Here the inventors show that expression of the tetraspanin CD9 increases markedly in PECs in mouse models of CGN and FSGS, and in kidneys from individuals diagnosed with these diseases. Cd9 gene targeting in PECs prevents glomerular damage in CGN and FSGS mouse models. Mechanistically, CD9 deficiency prevents the oriented migration of PECs into the glomerular tuft and their acquisition of CD44 and β1 integrin expression. These findings highlight a critical role for de novo expression of CD9 as a common pathogenic switch driving the PEC phenotype in CGN and FSGS, while offering a potential therapeutic avenue to treat these conditions. Accordingly, CD9 represents a reliable biomarker and as well as a biotargets in glomerulonephritides.

The application discloses a kind of biomarkers for evaluating systemic lupus erythematosus to lupus nephritis progression, prediction model and application, belong to lupus nephritis prediction technical field.The application provides a kind of for evaluating systemic lupus erythematosus to lupus nephritis progression prediction model, the prediction model is according to the ratio of biomarker CD8 / CD4 and the κ / λ ratio of naive B cell, carries out binary Logistic regression analysis, obtains LogitP value, by comparing the high and low of the LogitP value and critical value 0.66938, predicts systemic lupus erythematosus to lupus nephritis progression situation.The prediction model constructed in the application aims to identify the individuals in lupus patients who may develop into lupus nephritis.This innovative model not only provides important guidance in the diagnosis, prognosis prediction and efficacy evaluation of the disease, but also provides a new perspective for the clinical management of lupus nephritis.

The invention relates to the field of medical care informatics, and discloses a lupus nephritis condition monitoring system based on TWEAK and CD163 dynamic change, which comprises a data adaptation gateway module, a data rationality arbitration engine, a time sequence regularization engine module, a high-order feature extraction engine module and a risk layering module, the time sequence regularization engine module switches an interpolation or smoothing algorithm based on a qualitative result of the data rationality arbitration engine and a time domain where a data point is located so as to generate a continuous time function. Through the information processing architecture, the technical problem that sparse asynchronous original medical data is prone to being affected by outlier pollution and end point distortion is solved, and the accuracy of data processing is improved. The system reconstructs discrete data snapshots into continuous mathematical objects, provides a stable and analyzable technical basis for subsequent extraction of interpretable high-order dynamic features, and improves the credibility of clinical decision support.

This disclosure relates to RNAi agents capable of inhibiting complement factor B (CFB) gene expression. Pharmaceutical compositions containing CFB RNAi agents and methods of use thereof are also disclosed. The CFB RNAi agents disclosed herein may be conjugated to a targeted ligand containing an N-acetyl-galactosamine ligand to facilitate in vivo delivery to hepatocytes. RNAi agents can be used in methods of treating diseases, disorders, or conditions partially mediated by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membrane proliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), anti-glomerular basement membrane antibody disease (anti-GBM), ischemia-reperfusion injury and T-cell-mediated rejection in kidney transplantation (TCMR), anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD) including early and / or intermediate-stage AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated disorders.

The invention belongs to the technical field of traditional Chinese medicine preparations, and particularly relates to traditional Chinese medicine compound granules for treating lupus nephritis and a preparation method thereof. The formula of the traditional Chinese medicine compound granules comprises 25-35 parts of astragalus membranaceus, 8-12 parts of angelica sinensis, 8-12 parts of salvia miltiorrhiza, 25-35 parts of artemisia apiacea, 12-18 parts of caulis sinomenii, 25-35 parts of centella asiatica, 25-35 parts of raw malt and 25-35 parts of euonymus alatus. The medicinal materials are subjected to water extraction, extracting solutions are combined and concentrated into extract, maltodextrin, microcrystalline cellulose and soluble starch are selected as auxiliary materials to be dried and granulated, and the prepared traditional Chinese medicine compound granules are low in fine powder proportion, high in hardness and short in dissolution time. By adopting the dosage form of granules, not only are the characteristics of quick absorption and quick action of the decoction maintained, but also the defects of inconvenience in decoction, large dosage and easiness in mildewing during temporary use of the decoction are overcome, and the curative effect is remarkably improved.

The present invention relates to a nanoparticle comprising a nanomaterial and at least a first ligand and a second ligand tethered to the nanoparticle. The present invention also relates to a nanoparticle for use as a medicament or diagnostic agent. The present invention also relates to a nanoparticle for use in a method for preventing or treating a disease selected from the group consisting of diabetic nephropathy, glomerulonephritis, glomerular VEGF A dysregulation, endothelial VEGF A dysregulation, diabetic retinopathy, rheumatoid arthritis, age-related macular degeneration and cancer, such as breast cancer. Furthermore, the present invention relates to a method of preparing a nanoparticle.

Methods for treating primary glomerulonephritis, e.g., focal segmental glomerulosclerosis (FSGS), IgA nephropathy (IgAN) or mesangial proliferative glomerulonephritis (MsPGN) are provided.

This invention provides a traditional Chinese medicine composition for treating renal edema, pyelonephritis with ascites, and nephritis. It consists of over 20 herbs including Atractylodes lancea, Areca catechu, Saposhnikovia divaricata, and Alisma plantago-aquatica (specific formulation details can be found in the original text). It can be prepared as pills, granules, or decoctions for oral administration. Core efficacy: 1. Promotes diuresis and reduces swelling, eliminating renal ascites; 2. Clears heat and detoxifies, anti-inflammatory and antibacterial (synergistic effect on fungal infections and cervical erosion); 3. Regulates renal function and improves abnormal uric acid metabolism. Treatment plan: Mild cases: Use five basic formulas (①-⑤) composed of Codonopsis pilosula, Poria cocos, etc., taken three times daily; Severe cases: Use a potent diuretic formula containing Akebia trifoliata and Euphorbia pekinensis (one spoonful of pills twice daily); Treatment course is approximately one month, with a follow-up examination after three months. Advantages: Cure rate reaches 90%, low recurrence rate – pure traditional Chinese medicine preparation, no significant toxic side effects; also treats complications (fungal infection, cervical lesions). This treatment plan has been clinically verified through three generations and has significant efficacy in treating renal edema, ascites, and nephritis.

The invention relates to the technical field of medical image processing, in particular to a lupus nephritis curative effect prediction system based on multi-staining kidney biopsy pathological images. The system comprises a feature extraction module used for extracting image features of staining biopsy images of patients, a similarity analysis module used for distinguishing reference patients from non-reference patients according to the image features, a data preparation module used for forming training samples, and a data processing module used for processing the training samples. And the prediction module is used for performing model training based on the training data and predicting the healing probability of the target patient. According to the scheme, the model can be helped to pay more attention to training data of biopsy samples which are similar to biopsy samples of a target patient and are effectively different from biopsy samples of other reference patients, the characteristic of high heterogeneity existing in lupus nephritis is matched, the information mining effect of the biopsy sample image of lupus nephritis is improved, and the accuracy of the biopsy sample image of lupus nephritis is improved. And a doctor is assisted to accurately complete evaluation of specific typing and severity of lupus nephritis of a patient.

To provide a new method for treating lupus nephritis (LN), which improves renal response, reduces recurrence, prevents eventual end-stage renal disease (ESRD), and reduces the need for glucocorticoids.SOLUTION: WHAT IS CLAIMED IS: 1. A method of reducing lupus nephritis (LN) disease activity in a subject in need thereof, comprising administering to the subject a type I IFN receptor (IFNAR1) inhibiting agent. Preferably, the IFNAR1 inhibitors are human monoclonal antibodies specific for IFNAR1, such as anifrolumab.SELECTED DRAWING: None

The invention belongs to the field of medicinal chemistry and biological medicine, and discloses 3 '-O-sodium sulfonate quercetin as well as a preparation method and medical application thereof, the chemical name of the compound is 3, 5, 7, 4'-tetrahydroxyflavone-3 '-O-sodium sulfonate, the molecular formula is CHOSNa, and the compound is a novel derivative obtained by taking quercetin as a mother nucleus and carrying out specific sulfonation on 3'-hydroxyl and forming sodium salt. Quercetin and a sulfur trioxide-pyridine compound are used as main raw materials, sulfonation, salification, decoloration and freeze drying are performed, the process is mild, the specificity is high, the product yield is larger than or equal to 80%, the purity is larger than or equal to 99%, and the method is suitable for industrial production. The water solubility of the compound is improved by more than 4000 times compared with that of natural quercetin, the bioavailability is remarkably enhanced, and the compound has excellent anti-inflammatory activity, can specifically inhibit release of inflammatory factors such as TNF-alpha and IL-6, can be prepared into various dosage forms in compatibility with pharmaceutical auxiliary materials, is used for treating inflammation-related diseases such as inflammatory bowel diseases, rheumatoid arthritis and glomerulonephritis, and has wide application prospects. The invention provides an efficient and low-toxicity novel candidate drug for inflammation treatment, and has a good clinical application prospect.

Disclosed is a method for treating autoimmune diseases, wherein a therapeutically effective amount of a proteasome inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof is administered to a patient with autoimmune diseases. This method has a certain therapeutic effect on patients with autoimmune diseases, such as systemic lupus erythematosus, lupus nephritis (LN), and autoimmune hepatitis. The proteasome inhibitor or the pharmaceutically acceptable salt or pharmaceutical composition thereof has low toxicity, thereby showing excellent clinical application prospects.

The invention discloses a medicinal moxa composition for preventing and treating codiseases of beriberi and chronic glomerulonephritis. The medicinal moxa composition is prepared from radix aconiti carmichaeli, cortex cinnamomi, cornu cervi pantotrichum, rhizoma alismatis, radix achyranthis bidentatae and moxa. The medicinal moxa composition disclosed by the invention has remarkable external antibacterial and warming effects, consists of five yang warming medicines and one warming medicine, releases volatile components through combustion, and stimulates acupuncture points in combination with heating power, so that the dual effects of treating beriberi and chronic glomerulonephritis are achieved. The radix aconiti carmichaeli, cinnamon, cornu cervi pantotrichum, rhizoma alismatis, radix achyranthis bidentatae and wormwood in the formula form a unique synergistic effect mechanism in the external use process, so that the medicinal components directly reach the focus through skin penetration, and meanwhile, the qi and blood of the whole body are regulated. Through infrared radiation, volatile antibacterial components and a warming effect generated by combustion of the medicinal moxa, the dual treatment effects of external warming and dredging and internal qi and blood regulation are achieved, and a new thought is provided for treatment of foot fungal infection and kidney meridian dysfunction.

The invention relates to application of hispidulin or pharmaceutically acceptable salts, esters and solvates thereof in preparation of medicines for treating lupus nephritis. The invention develops a new application of the hispidulin, and proves the treatment effect of the hispidulin on lupus nephritis. Meanwhile, the invention verifies that the hispidulin can obviously improve the renal function indexes (including reducing urine protein, blood urea nitrogen and serum creatinine, increasing serum albumin and improving lipid metabolism) of lupus nephritis, can relieve renal pathological injuries (including reducing glomerular mesangial hyperplasia, basilar membrane thickening, renal tubule dilatation and interstitial inflammation infiltration), and can improve the renal function indexes of lupus nephritis. Kidney immune complex deposition can be reduced (including reduction of deposition of kidney IgG and complement C3), meanwhile, it is found for the first time that angiogenin-like protein 4 (Angptl4) is a key action target for treating lupus nephritis by means of the homospidulin, and the homospidulin plays a kidney protection role by down-regulating Angptl4 expression.

A composition comprising isolated Streptococcus pyogenes extracellular vesicles (EVs) suspended in a vehicle, for use in eliciting an adaptive immune response against group A streptococcus (GAS) in a subject. The EVs may comprise antigens MtsA, Spy_1228, PrsA1, PrsA2, SPy_0319 and / or GlnP. A composition comprising isolated S. pyogenes protein(s) MtsA, SPy_1228, PrsA1, PrsA2, GlnP, SPy_0319 and / or MalX. The compositions may be used for inducing protective immunity in a subject against a GAS infection, such as streptococcal pharyngitis, scarlet fever, impetigo, streptococcal meningitis, streptococcal sinusitis, necrotizing fasciitis, cellulitis, streptococcal toxic shock syndrome, rheumatic fever and post-streptococcal glomerulonephritis.

The invention relates to the field of traditional Chinese medicines, in particular to a preparation method and application of a nephritis medicine. According to the invention, the extract A (volatile oil), the extract B (ethanol extract) and the extract C (aqueous extract) are mixed according to a specific ratio (such as 4: 6 or 5: 5), so that a multi-component synergistic effect is exerted, and the anti-inflammatory, anti-oxidation and renal function protection effects are remarkably enhanced. Based on natural components of a traditional Chinese medicine compound and an optimized extraction process, side effects of common immunosuppressants or hormone drugs in western medicines are avoided, and safer treatment choices are provided.

Recent studies indicate that sIL7R is involved in the development of autoimmune diseases. The present invention provides methods and compositions for a novel antibody therapeutic against the soluble isoform of the interleukin 7 receptor (sIL7R), a potent driver of self-destructive immune responses that cause autoimmune diseases including multiple sclerosis, lupus nephritis, type I diabetes, rheumatoid arthritis, systemic lupus erythematosus, and many other autoimmune diseases. The present invention includes antibodies specific for sIL7R that inhibit SIL7R, a driver of autoimmunity, without inhibiting mIL7R, thereby reducing the severity of or preventing autoimmunity without activating immunosuppressive mechanisms.

The invention relates to an application of a reagent for detecting SRC expression in preparation of a product for diagnosing and treating lupus nephritis, SRC is highly expressed in a patient with lupus nephritis, when the expression level of SRC is reduced, ferroptosis of podocyte is remarkably relieved, ferroptosis related markers are remarkably reversed, the levels of Fe < 2 + > and MDA are reduced, the level of GSH is increased, and compared with a control group, the SRC expression level is remarkably reduced. The viability of podocyte is increased; the invention relates to application of a reagent for detecting CYBB expression in preparation of a product for diagnosing and treating lupus nephritis, CYBB is highly expressed in a patient suffering from lupus nephritis, when the expression level of CYBB is reduced, ferroptosis in podocytes is remarkably relieved, ferroptosis related markers are remarkably reversed, the levels of ACSL4, Fe < 2 + >, ROS and MDA are reduced, and the levels of GPX4 and GSH are increased, so that the effect of treating lupus nephritis is achieved. The polarization of M2 macrophages is promoted, the ferroptosis phenomenon is further relieved through the polarization of the macrophages, and the viability of podocytes is improved.

The application discloses a foot process identification method and device for electron microscope images of chronic kidney disease and terminal equipment, obtains the electron microscope pathological images of chronic kidney disease with labeled foot process position characteristics, and trains a preset deep network architecture through the electron microscope pathological images of chronic kidney disease to obtain a foot process identification model, so that when the electron microscope images of chronic kidney disease to be detected are obtained, the automatic identification of the foot process area corresponding to the electron microscope images to be detected can be realized through the obtained foot process identification model, and the automatic identification of the foot process area of the electron microscope images of chronic kidney disease is realized. The application accurately and quickly identifies the area corresponding to the foot process through the deep learning mode, improves the foot process identification efficiency of the electron microscope images of chronic kidney disease, is favorable to improving the pathological diagnosis and analysis efficiency of various types of glomerulonephritis for pathologists, and can reduce misdiagnosis and missed diagnosis caused by insufficient experience.

A method of treating a subject suffering from an immune-mediated disease (e.g., IgA nephropathy, primary membranous nephropathy, an antibody-mediated rejection, lupus nephritis, systemic lupus erythematosus (SLE), Graves' Disease, Myasthenia Gravis, Anti-PLA2R positive Membranous Glomerulonephritis (aMN), Pemphigus, Sjögren's syndrome, and / or Anti-NMDA encephalitis) by administering to the subject a regimen of at least five doses of felzartamab and measuring a level of CD19+CD27hiCD38hi plasmablasts, a level of CD19+ B lymphocytes, or levels of CD19+CD27hiCD38hi plasmablasts and CD19+ B lymphocytes in a blood sample taken from the subject.

Provided herein are methods of treating subjects having or suspected of having an autoimmune disease (e.g., systemic lupus erythematosus and / or lupus nephritis) using natural killer (NK) cells, and related compositions, uses, and articles of manufacture. In some aspects, the NK cell expresses a recombinant receptor, such as a CD19 directed chimeric antigen receptor (CAR).

The application discloses an antibody-antibiotic conjugate and application thereof, and a structural formula of the antibody-antibiotic conjugate is shown as formula (I) and is composed of a payload antibiotic, a monoclonal antibody targeting Kdo monosaccharide and an enzyme-sensitive linker; the antibody-antibiotic conjugate has strong affinity to Kdo antigen and can be combined with Staphylococcus aureus of different serotypes. Enzymatic treatment of the antibody-antibiotic conjugate can release free antibiotics to improve the bactericidal efficiency on Staphylococcus aureus; the antibody-antibiotic conjugate can effectively kill intracellular bacteria which are difficult to be affected by traditional small-molecule antibiotics through the mediation of the antibody; in the application of a Staphylococcus aureus-induced mouse pneumonia and nephritis model, the antibody-antibiotic conjugate can effectively remove bacteria in the lung and kidney, and the therapeutic effect is better than that of vancomycin. Therefore, the antibody-antibiotic conjugate has potential application in the development of Staphylococcus aureus infection drugs.

The application provides application of a TRPML1 specific small molecule inhibitor ML-SI3 in preparation of a medicine for treating or preventing nephritis. The application has the following beneficial effects: the TRPML1 specific small molecule inhibitor ML-SI3 can significantly reduce the serum anti-dsDNA antibody titer level of MRL / lpr lupus mice, reduce the urine albumin / creatinine ratio level, reduce the serum urea nitrogen level, reduce the swelling degree of the spleen and axillary lymph nodes, improve the kidney pathological changes, has a comprehensive protective effect on nephritis of MRL / lpr lupus mice, and provides application of a TRPML1 specific small molecule inhibitor ML-SI3 in preparation of a medicine for treating or preventing nephritis, provides a new medicine for treating lupus nephritis, and has good market value and clinical application prospect.

A composition comprising isolated Streptococcus pyogenes extracellular vesicles (EVs) suspended in a vehicle, for use in eliciting an adaptive immune response against group A streptococcus (GAS) in a subject. The EVs may comprise antigens MtsA, Spy_1228, PrsA1, PrsA2, SPy_0319 and / or GlnP. A composition comprising isolated S. pyogenes protein(s) MtsA, SPy_1228, PrsA1, PrsA2, GlnP, SPy_0319 and / or MalX. The compositions may be used for inducing protective immunity in a subject against a GAS infection, such as streptococcal pharyngitis, scarlet fever, impetigo, streptococcal meningitis, streptococcal sinusitis, necrotizing fasciitis, cellulitis, streptococcal toxic shock syndrome, rheumatic fever and post-streptococcal glomerulonephritis.

This invention provides the use of a reagent for detecting Effector CD4+ T cells in peripheral blood of subjects in the preparation of products for diagnosing membranous nephropathy, lupus nephritis, or ANCA-associated vasculitis. This invention also provides the use of peripheral blood Effector CD4+ T cells in the preparation of diagnostic models for membranous nephropathy, lupus nephritis, or ANCA-associated vasculitis. This invention detects this biomarker by flow cytometry, and the results show that Effector CD4+ T cells are significantly elevated in patients with membranous nephropathy, effectively distinguishing membranous nephropathy from healthy controls (validation set AUC 0.8098), and can help differentiate membranous nephropathy from lupus nephritis (validation set AUC 0.8686) and ANCA-associated vasculitis (validation set AUC 0.8968), and its level is correlated with the refractory nature of membranous nephropathy.